未治療肺結核患者に対するRFP・EB・INH9ヵ月に早期にSMを加えた組合せの治療成績

抄録

A 9-month regimen of daily ethambutol, isoniazid and rifampicin supplemented for thefirst one month by daily streptomycin and for the next two months by twice a weekstreptomycin (1SEHR/2S2EHR/6EHR) was given to 146 patients with newly diagnosedpulmonary tuberculosis, and the results were compared with those of 9-month regimenwith EB, INH, RFP (9EHR) as previously reported.
1. The rate of sputum conversion at 2 months and the 3 months was 78.8% and 96.5%, respectively. The result at 2 months was inferior to that (90.8%) of 9EHR regimen, butthe differences at 3 months and 4 months were not significant.
2. Improvement of chest-X-ray findings of two regimens was almost similar.
3. In the 43 out of 85 initially culture positive cases observed from 6 to 36 months afterthe completion of therapy, no bacteriological relapse was seen, but one patient relapsedradiographically.
4. Of the initial 146 patients, 36 (24.7%) had side effects and 26 (17.9%) had toterminate treatment because of drug toxicity, mainly due to streptomycin. It wasconcluded that the addition of streptomycin in the initial phase of short-coursechemotherapy had no effect on the rate of culture conversion and was contributing to theincreased incidence of adverse reactions, although background factors among the patientsstudied were a little bit different with those in 9 HER group.